The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Updated Genetic Score Based on 34 Confirmed Type 2 Diabetes Loci Is Associated With Diabetes Incidence and Regression to Normoglycemia in the Diabetes Prevention Program
Open accessAbstract
OBJECTIVE: Over 30 loci have been associated with risk of type 2 diabetes at genome-wide statistical significance. Genetic risk scores (GRSs) developed from these loci predict diabetes in the general population. We tested if a GRS based on an updated list of 34 type 2 diabetes–associated loci predicted progression to diabetes or regression toward normal glucose regulation (NGR) in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS: We genotyped 34 type 2 diabetes–associated variants in 2,843 DPP participants at high risk of type 2 diabetes from five ethnic groups representative of the U.S. population, who had been randomized to placebo, metformin, or lifestyle intervention. We built a GRS by weighting each risk allele by its reported effect size on type 2 diabetes risk and summing these values. We tested its ability to predict diabetes incidence or regression to NGR in models adjusted for age, sex, ethnicity, waist circumference, and treatment assignment. RESULTS: In multivariate-adjusted models, the GRS was significantly associated with increased risk of progression to diabetes (hazard ratio [HR] = 1.02 per risk allele [95% CI 1.00–1.05]; P = 0.03) and a lower probability of regression to NGR (HR = 0.95 per risk allele [95% CI 0.93–0.98]; P < 0.0001). At baseline, a higher GRS was associated with a lower insulinogenic index (P < 0.001), confirming an impairment in β-cell function. We detected no significant interaction between GRS and treatment, but the lifestyle intervention was effective in the highest quartile of GRS (P < 0.0001). CONCLUSIONS: A high GRS is associated with increased risk of developing diabetes and lower probability of returning to NGR in high-risk individuals, but a lifestyle intervention attenuates this risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hivert et al. (7) developed a 34-SNP T2D polygenic score. Similar to our β-cell cluster pPS findings, the authors determined that DPP participants in the highest T2D polygenic score quartile had reduced β-cell secretory response (IGR) at baseline compared with those in the lowest quartile; however, the 1-year longitudinal change in IGR was not significantly different between the two groups.”
From Increased genetic risk for β-cell failure is associated with β-cell function decline in people with prediabetes (2024) · cites this paper as [7]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493 · cited 1×
“C-statistic (28) and the integrated discrimination improvement (29) of the”
BackgroundThe Wellcome Trust Case Control Consortium, U.K.
Mossman, K. (2008) · Scientific American · doi:10.1038/scientificamerican0108-42a · Cited by 2,684
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk
DIAGRAM Consortium, Dupuis, J., GIANT Consortium, Global BPgen Consortium, Anders Hamsten on behalf of Procardis Consortium, the MAGIC investigators, Langenberg, C., Prokopenko, I., Saxena, R., Soranzo, N., et al. (2010) · Nature Genetics · doi:10.1038/ng.520 · Cited by 2,166
Self-citationWellcome Trust Case Control Consortium, Zeggini, E., Scott, L. J., Saxena, R., Voight, B. F., Marchini, J. L., Hu, T., de Bakker, P. I., Abecasis, G. R., Almgren, P., et al. (2008) · Nature Genetics · doi:10.1038/ng.120 · Cited by 1,864
Self-citationTwelve type 2 diabetes susceptibility loci identified through large-scale association analysis
The MAGIC investigators, Voight, B. F., The GIANT Consortium, Scott, L. J., Steinthorsdottir, V., Morris, A. P., Dina, C., Welch, R. P., Zeggini, E., Huth, C., et al. (2010) · Nature Genetics · doi:10.1038/ng.609 · Cited by 1,761
Self-citationPencina, M. J., & D'Agostino, R. B. (2004) · Statistics in Medicine · doi:10.1002/sim.1802 · Cited by 1,444 · cited 1×
“C-statistic (28) and the integrated discrimination improvement (29) of the”
BackgroundGreenland, P. (2008) · Statistics in Medicine · doi:10.1002/sim.2976 · Cited by 1,300
Clinical risk factors, DNA variants, and the development of type 2 diabetes
Lyssenko, V., Jonsson, A., Almgren, P., Pulizzi, N., Isomaa, B., Tuomi, T., Berglund, G., Altshuler, D., Nilsson, P., & Groop, L. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801869 · Cited by 938
Self-citationTCF7L2 Polymorphisms and Progression to Diabetes in the Diabetes Prevention Program
Florez, J. C., Jablonski, K. A., Bayley, N., Pollin, T. I., de Bakker, P. I. W., Shuldiner, A. R., Knowler, W. C., Nathan, D. M., & Altshuler, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062418 · Cited by 839
Self-citationVariants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus
Yasuda, K., Miyake, K., Horikawa, Y., Hara, K., Osawa, H., Furuta, H., Hirota, Y., Mori, H., Jonsson, A., Sato, Y., et al. (2008) · Nature Genetics · doi:10.1038/ng.207 · Cited by 776
Genotype score in addition to common risk factors for prediction of type 2 diabetes
Meigs, J. B., Shrader, P., Sullivan, L. M., McAteer, J. B., Fox, C. S., Dupuis, J., Manning, A. K., Florez, J. C., Wilson, P. W. F., D'Agostino, R. B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804742 · Cited by 759 · cited 2×
“This is in accordance with previous reports from general population cohorts showing that even if a GRS is associated with diabetes incidence, it adds little to the common known clinical risk factors (8,9).”
MethodResultSelf-citationUnoki, H., Takahashi, A., Kawaguchi, T., Hara, K., Horikoshi, M., Andersen, G., Ng, D. P. K., Holmkvist, J., Borch-Johnsen, K., Jørgensen, T., et al. (2008) · Nature Genetics · doi:10.1038/ng.208 · Cited by 725
(1999) · Diabetes Care · doi:10.2337/diacare.22.4.623 · Cited by 725
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge
GIANT consortium, Saxena, R., the MAGIC investigators, Hivert, M.-F., Langenberg, C., Tanaka, T., Pankow, J. S., Vollenweider, P., Lyssenko, V., Bouatia-Naji, N., et al. (2010) · Nature Genetics · doi:10.1038/ng.521 · Cited by 626
Self-citationUtzschneider, K. M., Prigeon, R. L., Faulenbach, M. V., Tong, J., Carr, D. B., Boyko, E. J., Leonetti, D. L., McNeely, M. J., Fujimoto, W. Y., & Kahn, S. E. (2009) · Diabetes Care · doi:10.2337/dc08-1478 · Cited by 572 · cited 1×
“[insulinogenic index/fasting insulin] (19).”
Self-citationRung, J., Cauchi, S., Albrechtsen, A., Shen, L., Rocheleau, G., Cavalcanti-Proença, C., Bacot, F., Balkau, B., Belisle, A., Borch-Johnsen, K., et al. (2009) · Nature Genetics · doi:10.1038/ng.443 · Cited by 479
Soranzo, N., Sanna, S., Wheeler, E., Gieger, C., Radke, D., Dupuis, J., Bouatia-Naji, N., Langenberg, C., Prokopenko, I., Stolerman, E., et al. (2010) · Diabetes · doi:10.2337/db10-0502 · Cited by 445
Common variants in WFS1 confer risk of type 2 diabetes
Sandhu, M. S., Weedon, M. N., Fawcett, K. A., Wasson, J., Debenham, S. L., Daly, A., Lango, H., Frayling, T. M., Neumann, R. J., Sherva, R., et al. (2007) · Nature Genetics · doi:10.1038/ng2067 · Cited by 381
Chip-based genotyping by mass spectrometry
Tang, K., Fu, D.-J., Julien, D., Braun, A., Cantor, C. R., & Köster, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10016 · Cited by 286 · cited 1×
“zation time-of-flight mass spectrometry on a Sequenom iPLEX platform (24).”
MethodBiostatistical methods : the assessment of relative risks
Lachin, J. M. (2000) · Cited by 272
Jablonski, K. A., McAteer, J. B., de Bakker, P. I. W., Franks, P. W., Pollin, T. I., Hanson, R. L., Saxena, R., Fowler, S., Shuldiner, A. R., Knowler, W. C., et al. (2010) · Diabetes · doi:10.2337/db10-0543 · Cited by 271
Self-citationGenome-wide association studies in type 2 diabetes
McCarthy, M. I., & Zeggini, E. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0027-4 · Cited by 233 · cited 1×
“Widespread collaboration and recent advances in genetic knowledge and technology have permitted discovery of many new loci associated with risk of type 2 diabetes (1,2).”
BackgroundCornelis, M. C., Qi, L., Zhang, C., Kraft, P., Manson, J., Cai, T., Hunter, D. J., & Hu, F. B. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-8-200904210-00008 · Cited by 230 · cited 1×
“netic scores for type 2 diabetes prediction (9,25), we created a weighted GRS”
MethodA method for checking regression models in survival analysis based on the risk score
Gr�nnesby, J. K., & Borgan, �. (1996) · Lifetime Data Analysis · doi:10.1007/bf00127305 · Cited by 209 · cited 2×
“Calibration tests of the Cox models were performed using methods described by Grønnesby and Borgan (26) and Parzen and Lipsitz (27);”
MethodRegression from pre-diabetes to normal glucose regulation in the diabetes prevention program
Perreault, L., Kahn, S. E., Christophi, C. A., Knowler, W. C., Hamman, R. F., & the Diabetes Prevention Program Research Group (2009) · Diabetes Care · doi:10.2337/dc09-0523 · Cited by 209
Self-citationBiostatistical Methods: The Assessment of Relative Risks
Lachin, J. M. (2000) · Wiley Series in Probability and Statistics · doi:10.1002/9780470317051 · Cited by 200
de Miguel-Yanes, J. M., Shrader, P., Pencina, M. J., Fox, C. S., Manning, A. K., Grant, R. W., Dupuis, J., Florez, J. C., D'Agostino, R. B., Cupples, L. A., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1265 · Cited by 172
Self-citationExtension of Type 2 Diabetes Genome-Wide Association Scan Results in the Diabetes Prevention Program
Moore, A. F., Jablonski, K. A., McAteer, J. B., Saxena, R., Pollin, T. I., Franks, P. W., Hanson, R. L., Shuldiner, A. R., Knowler, W. C., Altshuler, D., et al. (2008) · Diabetes · doi:10.2337/db08-0284 · Cited by 103
Self-citationGenomics of type 2 diabetes mellitus: implications for the clinician
Stolerman, E. S., & Florez, J. C. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.129 · Cited by 99 · cited 1×
“Widespread collaboration and recent advances in genetic knowledge and technology have permitted discovery of many new loci associated with risk of type 2 diabetes (1,2).”
BackgroundSelf-citationByrne, C. D., Wareham, N. J., Brown, D. C., CLARK, P. M. S., Cox, L., Day, N., Palmer, C., Wang, T. W. M., Williams, D. R. R., & Hales, C. N. (1994) · Diabetologia · doi:10.1007/bf00400944 · Cited by 84 · cited 1×
“[(insulin at 30 min) 2 (insulin at 0 min)]/[(glucose at 30 min) 2 (glucose at 0 min)] (18).”
A Global Goodness‐of‐Fit Statistic for Cox Regression Models
Parzen, M. I., & Lipsitz, S. R. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00580.x · Cited by 73 · cited 2×
“Calibration tests of the Cox models were performed using methods described by Grønnesby and Borgan (26) and Parzen and Lipsitz (27);”
MethodTesting of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program
Florez, J. C., Jablonski, K. A., McAteer, J. B., Sandhu, M. S., Wareham, N. J., Barroso, I., Franks, P. W., Altshuler, D., & Knowler, W. C. (2007) · Diabetologia · doi:10.1007/s00125-007-0891-x · Cited by 70
Self-citationPrediction of Incident Diabetes Mellitus in Middle-aged Adults: The Framingham Offspring Study
Wilson, P. W. F. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.10.1068 · Cited by 4 · cited 1×
“Covariates included in the clinical model were based on previous clinical models in a general population cohort (30).”
MethodSelf-citation
Cited by
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
Zheng, Y., Ley, S. H., & Hu, F. B. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.151 · Cited by 5,697
O’Sullivan, J. W., Raghavan, S., Marquez-Luna, C., Luzum, J. A., Damrauer, S. M., Ashley, E. A., O’Donnell, C. J., Willer, C. J., Natarajan, P., & on behalf of the American Heart Association Council on Genomic and Precision Medicine; Council on Clinical Cardiology; Council on Arteriosclerosis, T. A. V. B. C. O. C. R. A. I. C. O. L. A. C. H. A. C. O. P. V. D. (2022) · Circulation · doi:10.1161/cir.0000000000001077 · Cited by 412
Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetes Care · doi:10.2337/dci20-0022 · Cited by 400
Self-citationDiabetes: Advances in Diagnosis and Treatment
Nathan, D. M. (2015) · JAMA · doi:10.1001/jama.2015.9536 · Cited by 384
Murea, M., Ma, L., & Freedman, B. I. (2012) · The Review of Diabetic Studies · doi:10.1900/rds.2012.9.6 · Cited by 366
Metadata
- Authors
- Hivert, M.-F., Jablonski, K. A., Perreault, L., Saxena, R., McAteer, J. B., Franks, P. W., Hamman, R. F., Kahn, S. E., Haffner, S., the DIAGRAM Consortium, Meigs, J. B., Altshuler, D., Knowler, W. C., Florez, J. C., & for the Diabetes Prevention Program Research Group
- Affiliations
- Université de Sherbrooke (CA)
- George Washington University (US)
- University of Colorado Anschutz (US)
- Broad Institute (US)
- Lund University (SE)
- Colorado School of Public Health (US)
- University of Washington (US)
- Baylor College of Medicine (US)
- Harvard University (US)
- National Institutes of Health (US)
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-03-22
- Volume
- 60
- Issue
- 4
- Pages
- 1340-1348
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3064108
- OpenAlex
- W2119445047
- Cited by
- 191
- References
- 36
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 5 · 2023: 10 · 2022: 8 · 2021: 13 · 2020: 9 · 2019: 13 · 2018: 10 · 2017: 13 · 2016: 14 · 2015: 17 · 2014: 19 · 2013: 11 · 2012: 30
- FWCI
- 13.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- Site cant be reached (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK072041, K24DK080140, P30DK017047)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, polygenic risk score, Diabetes Prevention Program, diabetes incidence, lifestyle intervention, metformin, insulinogenic index, beta-cell function, genetic susceptibility
- MeSH terms
- Diabetes Mellitus, Type 2, Exercise Therapy, Genotype, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Metformin, Weight Loss, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.